LAT1 expression in non-small-cell lung carcinomas: Analyses by semiquantitative reverse transcription-PCR (237 cases) and immunohistochemistry (295 cases)

Lung Cancer

Volumn 68, Issue 1, 2010, Pages 58-65

  Takeuchi, Katsuyuki ^a   Ogata, Sho ^b   Nakanishi, Kuniaki ^b   Ozeki, Yuichi ^b   Hiroi, Sadayuki ^b   Tominaga, Susumu ^b   Aida, Shinsuke ^c   Matsuo, Hirotaka ^b   Sakata, Tsuneaki ^d   Kawai, Toshiaki ^b  

^a Graduate School of Science and Technology   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^c NATIONAL DEFENSE MEDICAL COLLEGE HOSPITAL   (Japan)

^d HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Immunohistochemistry; LAT1; mRNA; Non small cell lung carcinoma; Prognosis; Protein; RT PCR

Indexed keywords

AMINO ACID TRANSPORTER; AMINO ACID TRANSPORTER 1; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CELL MEMBRANE; CONTROLLED STUDY; CYTOPLASM; FEMALE; GENE EXPRESSION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LARGE NEUTRAL AMINO ACID-TRANSPORTER 1; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77649192122     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.05.020     Document Type: Article

References (19)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Toloza E.M., and D'Amico T.A. Targeted therapy for non-small cell lung cancer. Semin Thorac Cardiovasc Surg 17 (2005) 199-204
3. Christensen H.N. Role of amino acid transport and countertransport in nutrition and metabolism. Physiol Rev 70 (1990) 43-77
4. Chillaron J., Roca R., Valencia A., Zorzano A., and Palacin M. Heteromeric amino acid transporters: biochemistry, genetics, and physiology. Am J Physiol Renal Physiol 281 (2000) F995-F1018
5. Kanai Y., and Endou H. Functional properties of multispecific amino acid transporters and their implications to transporter-mediated toxicity. J Toxicol Sci 28 (2003) 1-17
6. Kanai Y., and Endou H. Heterodimeric amino acid transporters: molecular biology and pathological and pharmacological relevance. Curr Drug Metab 2 (2001) 339-354
7. Kanai Y., Segawa H., Miyamoto K., Uchino H., Takeda E., and Endou H. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 273 (1998) 23629-23632
8. Mastroberardino L., Spindler B., Pfeiffer R., Skelly P.J., Loffing J., Shoemaker C.B., et al. Amino-acid transport by heterodimers of 4F2hc/CD98 and members of a permease family. Nature 395 (1998) 288-291
9. Ohkame H., Masuda H., Ishii Y., and Kanai Y. Expression of l-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2hc) in liver tumor lesions of rat models. J Surg Oncol 78 (2001) 265-271
10. Parmacek M.S., Karpinski B.A., Gottesdiener K.M., Thompson C.B., and Leiden J.M. Structure, expression and regulation of the murine 4F2 heavy chain. Nucleic Acids Res 17 (1989) 1915-1931
11. Sang J., Lim Y.P., Panzica M., Finch P., and Thompson N.L. TA1, a highly conserved oncofetal complementary DNA from rat hepatoma, encodes an integral membrane protein associated with liver development, carcinogenesis, and cell activation. Cancer Res 55 (1995) 1152-1159
12. Shennan D.B., Thomson J., Barber M.C., and Travers M.T. Functional and molecular characteristics of system L in human breast cancer cells. Biochim Biophys Acta 1611 (2003) 81-90
13. Campbell W.A., and Thompson N.L. Overexpression of LAT1/CD98 light chain is sufficient to increase system l-amino acid transport activity in mouse hepatocytes but not fibroblasts. J Biol Chem 276 (2001) 16877-16884
14. Nakanishi K., Matsuo H., Kanai Y., Endou H., Hiroi S., Tominaga S., et al. LAT1 expression in normal lung and in atypical adenomatous hyperplasia and adenocarcinoma of the lung. Virchows Arch 448 (2006) 142-150
15. Travis W.D., Colby T.V., Corrin B., Shimosato T., and Brambilla E. The World Health Organization: Histological Typing of Lung and Pleural Tumours. third ed. (1999) p. 36
16. Sobin I.H., and Wittekind C. International Union against Cancer: TNM Classification of Malignant Tumours. 6th ed. (2002), Wiley-Liss Inc., New York
17. Kaira K., Oriuchi N., Imai H., Shimizu K., Yanagitani N., Sunaga N., et al. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer 98 (2008) 742-748
18. Matsuo H., Tsukada S., Nakata T., Chairoungdua A., Kim D.K., Cha S.H., et al. Expression of a system L neutral amino acid transporter at the blood-brain barrier. Neuroreport 11 (2000) 3507-3511
19. Segawa H., Fukasawa Y., Miyamoto K., Takeda E., Endou H., and Kanai Y. Identification and functional characterization of a Na+-independent neutral amino acid transporter with broad substrate selectivity. J Biol Chem 274 (1999) 19745-19751